How ‘green’ inhalers could evade Biden’s drug pricing legacy
The Biden administration has reformed Medicare, gone after bogus drug patents and pushed pharmaceutical companies to reduce inhaler costs for patients. “Climate-friendly inhalers” could jeopardize those wins.
The Biden administration has reformed Medicare, gone after bogus drug patents and pushed pharmaceutical companies to reduce inhaler costs for patients. “Climate-friendly inhalers” could jeopardize those wins.
